Fellows Poster Walks are led by expert faculty who will review and put into context the most significant and thought-provoking science at the meeting, while providing a venue for networking and informal discussion.
To register for a Fellows Poster Walk, select the Register button on the right-hand side in order to add a complimentary ticket to your registration. *
| Fellows Poster Walks: Prostate Cancer Thursday, February 14 - 5:20 PM - 6:35 PM |
|
| James Gulley, MD, PhD - National Cancer Institute |
Abstract #57 - Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. Abstract #74 - Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. Abstract #34 - Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC). Abstract #114 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). Abstract #135 - Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer. Abstract #147 - P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) previously treated with sipuleucel-T: Evaluation of antigen-presenting cell (APC) activation. Abstract #85 - Safety profile of poxviral vaccines: NCI experience. Abstract #102 - A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. Abstract #11 - Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). Abstract #19 - Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. |
| Jason Efstathiou, MD, DPhil - Massachusetts General Hospital |
Abstract #1 - Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up. |
| Fellows Poster Walks: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma Friday, February 15 - 5:30 PM - 6:45 PM |
|
| Max Meng, MD -University of California, San Francisco |
Abstract ID (Temp. Abst. ID): 247(107129) - Genomic characterization of metastatic urothelial carcinoma. Abstract ID (Temp. Abst. ID): 249(106541) - Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for invasive bladder cancer (BC): Japan Clinical Oncology Group Study, JCOG0209. Abstract ID (Temp. Abst. ID): 316(107654) - Perioperative management of radical cystectomy patients: A questionnaire survey of the American Urological Association members. Abstract ID (Temp. Abst. ID): 311(107552) - Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. Abstract ID (Temp. Abst. ID): 309(107525) - Efficacy and safety of valrubicin in non–muscle-invasive bladder cancer in older and younger patients. Abstract ID (Temp. Abst. ID): 306(107515) - A multi-analyte assay for the noninvasive detection of bladder cancer. Abstract ID (Temp. Abst. ID): 301(107472) - Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). Abstract ID (Temp. Abst. ID): 300(107461) - Exome sequencing of extreme phenotypes to identify variants predictive of response to chemotherapy in bladder cancer. Abstract ID (Temp. Abst. ID): 299(107454) - Using micro-RNA expression to predict response to neoadjuvant chemotherapy in urothelial carcinoma of the bladder. Abstract ID (Temp. Abst. ID): 292(107394) - HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2. Abstract ID (Temp. Abst. ID): 275(107205) - Muscle invasive bladder cancer in the elderly: Treatment and prognosis in a prospective cohort study. Abstract ID (Temp. Abst. ID): 257(106483) - Survival of upper tract urothelial carcinoma: A population-based analysis. |
| Noah Hahn, MD – University of Indiana Melvin and Bren Simon Cancer Center |
Testicular Cancer Abstract 319 (107239) – Prediction of relapse in stage I nonseminomatous germ cell tumors (NSGCT) by CXCL12: Results from the MRC TE08 and TE22 clinical trials – lead author Duncan Charles Gilbert Abstract 320 (107646) – Cost analysis of adjuvant management strategies in early-stage testicular seminoma – lead author John A. Cox Abstract 324 (107014) – A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor (NSCGT) – lead author Elizabeth O’Donnell Abstract 325 (107110) – A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy – lead author Elizabeth O’Donnell Abstract 336 (107553) – Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT) – lead author Darren Richard Feldman Penile Cancer Abstract 326 (107181) – Inguinal lymph node dissection for penile carcinoma: Postoperative complications using a validated classification system – lead author Isuru Sampath Jayaratna Abstract 332 (107441) – Treatment patterns for patients with localized (T1-T2) penile squamous cell carcinoma in the United States – lead author Brittney Diane Barbosa Abstract 340 (107640) – Treatment of metastatic penile cancer in the adjuvant setting with ifosfamide, paclitaxel, and cisplatin: A single institution experience – lead author Aine O’Reilly |
*Poster Walks are limited to Fellows, Residents, and Junior Faculty only.
